Introduction
The use of transgenic mice and mice bearing targeted gene disruptions (knockout mice) has given rise to current paradigms for the mechanistic evaluation of processes relevant to both physiology (e.g., embryogenesis, growth control and dierentiation, morphogenesis) and pathology (e.g., neurodegenerative disease, hypertension, rheumatoid arthritis, neoplasia). Over 20 years ago, the combination of murine embryo culture with the techniques of reimplantation, DNA microinjection, and mammalian retrovirus manipulation resulted in the generation of the ®rst transgenic mice. These animals were produced by embryo infection and microinjection methodologies (Brinster, 1972; Jaenisch, 1976; Gordon et al., 1980) . Three years later, the ®rst example of a tissue-speci®c transgenic animal was published (Igk gene expression in murine spleen), thus establishing the re®ned capacity for examining exogenous gene expression in models with greater in vivo relevance (Brinster et al., 1983) . Then, in 1984, the ®rst transgenic animal was generated for the purpose of evaluating the relevance of a cellular protooncogene, c-myc, to mammary development and tumorigenesis (Stewart et al., 1984) . Subsequently, a burgeoning ®eld of mammary-speci®c transgenic murine models has been generated and characterized, greatly advancing our understanding of the molecular basis for the contribution of growth factors, oncogenes and tumor suppressor genes to the pathogenesis of breast cancer.
In this review, we will address two dierent c-myccontaining bitransgenic murine models (c-myc/tgfa and c-myc/p53 +/7 ) that our group McCormack et al., 1998) and two other groups (Elson et al., 1995; Sandgren et al., 1995) have generated. We shall also discuss the contributions these models have made to our understanding of breast cancer and of molecular pathways that are in¯uenced by the c-myc oncogene.
c-myc oncogene, the mammae and breast cancer c-Myc is a 439-amino acid nuclear transcription factor that interacts with DNA when heterodimerized with the Max protein. This heterodimerization is required for c-Myc-mediated cell cycle progression, transformation, and apoptosis, and is facilitated via C-terminal leucine zipper and basic helix-loop-helix motifs (Harrington et al., 1994; Packham et al., 1995) . cMyc has been demonstrated to contribute to a number of important cellular functions, including cell cycle progression, apoptosis and DNA anabolism. In addition, c-Myc plays a role in cellular transformation via both transcriptional upregulation and transcriptional repression of target genes. The former occurs through established E-box or other less well-de®ned promoter elements, while the latter is most likely mediated through initiator elements or in conjunction with other transcriptional modulators such as AP-2 and C/EBP (Facchini et al., 1998; Dang, 1999) . The Dual Signal model, as proposed by Gerard Evan, suggests that induction of apoptosis is an obligate function of c-myc expression and acts as a potent mechanism for the suppression of tumorigenesis (Evan et al., 1993) . c-Myc expression, coupled with any block to cellular proliferation, such as growth arrest caused by serum or growth factor deprivation, has been demonstrated in ®broblasts to result in apoptosis, independent of cell cycle phase (Evan et al., 1992) . However, this does not occur in benzo[a]pyreneimmortalized human mammary epithelial cells (MECs) transfected with c-myc and deprived of epidermal growth factor (EGF) (Nass et al., 1998) . Instead, these cells arrest in the G1 phase of the cell cycle and do not undergo apoptosis.
c-Myc expression is increased in the normal mammary gland during pregnancy-related prolifera-tion, it is absent in dierentiated mammary alveolar cells during lactation, and it is again increased during the normal apoptotic mammary involution process (Strange et al., 1992) . c-Myc is believed to be a nuclear mediator of mitogenic signals incident upon cells from various receptor systems and is contributory to, but not sucient for, mammary epithelial cell transformation (Leder et al., 1986; Telang et al., 1990) . Constitutive expression of c-myc has been shown to partially transform both mouse and human MECs, such that they grow in soft agar in response to EGF and transforming growth factor a (TGFa) (anchorageindependent growth), and are no longer as dependent upon these growth factors for anchorage-dependent growth as are the parental, non-transfected cells (Telang et al., 1990; Valverius et al., 1990) . Furthermore, deregulated expression of c-myc, via multiple mechanisms, including translocation, proviral insertion, gene ampli®cation, point mutation, and direct transcriptional eects, is a common feature of many human cancers (including breast, lung, liver and colon), and is thought to contribute to cellular proliferation and transformation when apoptosis is suppressed (Evan et al., 1992; Santoni-Rugiu et al., 1998; Dang, 1999) . In human breast cancers, c-myc is ampli®ed in approximately 16%, rearranged in approximately 5%, and overexpressed in the absence of gross locus alteration in nearly 70% of all cases, thus suggesting its importance in the genesis and/or progression of breast cancer (Nass et al., 1997; Deming et al., 1999) .
Three groups have independently developed transgenic mice that express the c-myc oncogene in a mammary-associated (MMTV-c-myc) or mammaryspeci®c (WAP-c-myc) context (Stewart et al., 1984; Schoenenberger et al., 1988; Sandgren et al., 1995) . In addition to these c-myc transgenic animals, another group has developed a mouse model, using a mammary tissue reconstitution method, in which the v-myc oncogene is expressed by a retrovirus throughout the reconstituted mammae (Edwards et al., 1988) . Both groups that have generated WAP-c-myc transgenic mice have reported a high incidence of mammary tumors; Schoenenberger described the tumors as adenocarcinomas, while Sandgren described them as solid carcinomas. In both cases, tumor incidence approached 100% in multiparous animals, with all virgin animals remaining tumor-free over the observation period (to 14 months of age). Additionally, both groups reported the expression of the c-myc transgene in both neoplastic mammary tissue as well as in mammary tissue from normal female mice during the latter part of pregnancy and throughout lactation (Schoenenberger et al., 1988; Sandgren et al., 1995) . These ®ndings are as expected owing to the temporal window for the hormone-driven activity of the whey acid protein (WAP) gene promoter. Stewart et al., (1984) reported the presence of mammary adenocarcinomas in 100% of multiparous F1 female transgenic mice derived from founder 141-3 in which the murine mammary tumor virus long terminal repeat (MMTV-LTR) had been placed immediately upstream of the mouse c-myc locus containing all three exons. Interestingly, WAP-c-myc and MMTV-c-myc female transgenic mice display lengthy tumor latencies and exquisite dependence upon pregnancy for tumor development, suggestive not only of the contribution but also of the insuciency of c-myc in mammary tumorigenesis.
Transforming growth factor a, the mammae and breast cancer TGFa is a secreted, 50-amino acid glycoprotein, derived from an active, membrane-bound 160-amino acid precursor. TGFa demonstrates a high level of homology (*42%) with EGF (Martinez-Lacaci et al., 1999) , and both molecules bind the epidermal growth factor receptor (EGFR) with high anity. The growth factor family to which TGFa and EGF belong is now known to contain about 15 mammalian genes (Martinez-Lacaci et al., 1999) . TGFa binding to EGFR (also termed c-ErbB1) has been demonstrated to result in receptor homodimerization as well as heterodimerization between c-ErbB1 and c-ErbB2, cErbB3 and/or c-ErbB4, when present. Receptor dimerization leads to receptor autophosphorylation and activation of downstream signalling pathways including p42/p44 MAPK, JNK/SAPK, PI3K, PLC and cAMP/PKA (Dickson and Lippman, 1995; Siegel et al., 1998; Martinez-Lacaci et al., 1999) . TGFa is expressed in normal murine mammae within the basal cells of the epithelium and the terminal cells of the end buds (Snedeker et al., 1991; Martinez-Lacaci et al., 1999) . It is also present in murine and human mammae during pregnancy (Liscia et al., 1990) and has been demonstrated to have similar growth eects upon human and murine mammary epithelial cells in vitro (Salomon et al., 1987; Bates et al., 1990; Valverius et al., 1989) . Exogenous TGFa expression has also been reported to contribute to the transformation of murine MECs that have been previously immortalized, suggesting that growth factor expression can cooperate with other established genetic alterations in mammary tissue in transforming pathways McGeady et al., 1989) . Early evidence demonstrated increased TGFa expression in mammary tumors versus normal mammary gland Arteaga et al., 1988; Bates et al., 1988; Travers et al., 1988) ; however, the current paradigm for EGF family growth factor participation in breast cancer also involves the establishment of a pro-survival, proproliferative, autocrine stimulatory loop with EGFR. The EGFR has also been found to be overexpressed with or without gene ampli®cation in approximately 50% of breast cancers (Harris et al., 1988; Dahiya et al., 1998; Martinez-Lacaci et al., 1999 , De Luca et al., 1999 .
Three groups have independently developed transgenic mouse models in which the TGFa growth factor is expressed in a metal ion-inducible, general tissue context (MT1-tgfa) (Sandgren et al., 1990; Jhappan et al., 1990) , a mammary-associated context (MMTVtgfa) (Matsui et al., 1990) , or a mammary-speci®c context (WAP-tgfa) (Sandgren et al., 1995) . The two groups that generated MT1-tgfa transgenic mice used rat and human tgfa under the control of the heavymetal inducible murine metallothionein (MT) promoter. Each group reported that TGFa expression signi®cantly in¯uenced mammary gland development and MEC proliferation as examined using mammary gland whole mounts. In addition, TGFa expression contributed to mammary alveolar hyperplasia and c-Myc in bitransgenic murine mammary tumor models MH Jamerson et al mammary adenocarcinoma in multiparous female transgenic mice (Sandgren et al., 1990; Jhappan et al., 1990) . MMTV-LTR-driven expression of the tgfa transgene was also shown to contribute to mammary alveolar hyperplasia in virgin female mice and to mammary adenocarcinoma in multiparous female mice. Furthermore, TGFa protein expression was con®rmed and a TGFa/EGFR autocrine loop was suspected due to the increased presence of EGFR mRNA in areas of increased expression of the transgene (Matsui et al., 1990) . Finally, results from the characterization of the WAP-tgfa transgenic model suggest that constitutive tgfa expression accelerates mammary development, impedes apoptotic involution, and contributes to mammary transformation by acting as a survival factor for dierentiated murine MECs (Sandgren et al., 1995) . Signi®cantly, the requirement for pregnancy and the extended tumor latency for TGFa transgenic models illustrates that TGFa is likely to be incapable of serving as the sole cause of mammary cancers. Rather, TGFa overexpression is likely to be one promotional step along a multistep oncogenic pathway(s). Therefore, it is particularly interesting that the tumorigenicity of cancer cell lines (liver) has been associated with the dual overexpression of tgfa and cmyc, suggesting a possible cooperativity between these two genes (Lee et al., 1991) .
MMTV-c-myc/MT-tgfa and WAP-c-myc/WAP-tgfa bitransgenic mice
The MMTV-c-myc/MMTV-v-Ha-ras cross generated in 1987 was the ®rst c-myc-containing bitransgenic mouse (Sinn et al., 1987) . Characterization of this bitransgenic mouse model demonstrated that deregulated c-myc expression synergized with deregulated v-Ha-ras expression to both accelerate mammary tumorigenesis and abrogate the requirement for pregnancy in this process. Interestingly, mammary tumors were demonstrated in both virgin female and male bitransgenic mice, despite a further delay in tumor onset in males of nearly 2 months. Eight years later, our group and another group reported the generation and characterization of mice bitransgenic for c-myc and tgfa, lending support to the notion that signalling through the EGFR and/or activation of Ras could synergize with deregulated c-myc expression in mammary tumorigenic processes Sandgren et al., 1995) . The MMTV-c-myc/MT-tgfa bitransgenic mice from our laboratory develop multiple mammary adenocarcinomas with a much reduced latency, and do so in the absence of any requirement for pregnancy or ovarian hormone stimulation. These mammary adenocarcinomas grew without requirement for estrogen (i.e., without delayed tumor growth in ovariectomized bitransgenic female mice) despite being estrogen receptor positive, as shown by estrogen receptor ligand-binding assay. Furthermore, histological evaluation of mammary gland tissue from both female and male animals as young as 5 weeks of age evidenced both hyperplastic and neoplastic changes in areas of transgene co-expression . The complete absence of normal mammary tissue in bitransgenic animals and the ability of bitransgenic mammary tissue from 3 week-old mice to form tumors in athymic mice suggest that these two important, mammary gland-relevant genes (c-myc and tgfa) are capable of synergistically transforming the mammary epithelium, apparently requiring minimal, if any, additional genetic alterations (Amundadottir et al., , 1996a . These studies also demonstrated that cmyc and tgfa are capable of further cooperation to drive hyperplastic and neoplastic changes in the murine salivary glands. This was not seen in single transgenic animals carrying c-myc or tgfa . Characterization of the WAP-c-myc/WAP-tgfa bitransgenic model con®rmed the potent synergy of these two genes in promoting and accelerating mammary tumor formation, when compared with the relevant single transgenic animals. Furthermore, the power of this cooperative interaction between c-myc and tgfa is demonstrated in both our model and the WAP-based model since both male and virgin female bitransgenic animals develop mammary tumors Sandgren et al., 1995) . The WAP promoter utilized in the latter study to drive the expression of the c-myc and tgfa transgenes is often presumed to drive transgene expression only in the latter part of pregnancy and throughout lactation and involution. However, the presence of mammary tumors in male and virgin female bitransgenics suggests that the MMTV and WAP promoters may be slightlỳ leaky', in the sense that minimal transgene expression may still occur even in the absence of ovarian hormone stimulation or that minimal promoter activity may be present during estrous in these mice. Subsequent work in our laboratory with single transgenic mice, c-myc/tgfa bitransgenic mice, and cell lines derived from transgenic mouse mammary tumors, has led to the hypothesis that TGFa can cooperate with c-Myc in promoting cell cycle progression and can act to suppress c-Myc-induced apoptosis (Amundadottir et al., 1996b; Nass et al., 1996 Nass et al., ,1998 . Our results, together with those from another group, have suggested that transformation, maintenance of transformation, and suppression of apoptosis in c-mycoverexpressing mammary tumor cell lines derived from transgenic animals may require signalling through the p42/p44 MAPK and PI3K pathways, both of which are targets of the activated EGFR (Amundadottir et al., 1998; Wang et al., 1999) . In situ end labeling apoptosis assays (TUNEL staining) in paranembedded mammary tumor sections from transgenic animals indicated the presence of apoptotic mammary cells in c-myc transgenic tumors and their near absence in tumors from the tgfa and c-myc/tgfa transgenic mice (Amundadottir et al., 1996b) . Data from our tumor cell lines indicate that coexpression of c-myc and tgfa results in increased cell proliferation under anchoragedependent and anchorage-independent conditions, a reduced requirement for exogenous growth factor stimulation, and greatly decreased apoptosis. This protection from apoptosis is abrogated when EGFR signalling is blocked by addition of PD153035 ± a speci®c, synthetic EGFR tyrosine kinase inhibitor. Furthermore, the myc83 cell line, and an additional ®ve other cell lines derived from mammary tumors in c-myc transgenic mice, were signi®cantly more apoptotic than cell lines derived from either tgfa or c-myc/tgfa bitransgenic mammary tumors. The frequency of apoptotic cells could be considerably suppressed by the addition of exogenous TGFa or EGF. Conversely, apoptosis was considerably accentuated when EGFR signalling was blocked via PD153035. This augmentation of apoptosis was sensitive to reversal by addition of the survival factor basic ®broblast growth factor (bFGF), which interacts with its own speci®c family of receptors and does not associate with EGFR (Amundadottir et al., 1996b) .
Molecular characterization of apoptosis in c-mycoverexpressing murine MECs derived from the MMTVc-myc transgenic mice led to the recognition that Bcl-x L , an anti-apoptotic member of the Bcl-2 family of apoptosis regulatory proteins, is a likely mediator of TGFa and EGF-directed protection against c-mycdriven apoptosis. Bcl-x L mRNA and protein levels were elevated with TGFa or EGF treatment of these cmyc-expressing cell lines, and expression of this antiapoptotic molecule was signi®cantly diminished with growth factor removal, TGFb treatment, or PD153035 treatment. In addition, levels of Bax (a pro-apoptotic Bcl-2 family member) and p53 appeared relatively high and unchanged, while Bcl-2 and Bcl-x S (another proapoptotic Bcl-2 family member) levels remained low or undetectable with these aforementioned treatments (Nass et al., 1996) . The work in our laboratory has led to the following models for the cooperation between c-Myc and TGFa in proliferation and apoptosis in the mouse mammary gland: First, with respect to proliferation, deregulated c-Myc may drive cellular proliferation by upregulating/inducing cyclin A2, E2F1, cyclin E, cdc25A phosphatase, and CAK-activating partner cdk7, and by lowering p27 levels resulting in cdk2 activation. In contrast, TGFa overexpression leads to the induction of cyclin D1 and, subsequently, the activation of cdk4/6 (Liao et al., 2000) . The combination of these two eects may further deregulate the cell cycle. Second, with respect to apoptosis, deregulated cmyc expression may promote apoptosis by directly inducing p53 expression, and by directly or indirectly inducing Bax expression. Bax has been shown to be directly responsive to p53 and also to be a potential target for c-Myc induction because of the location of four E-boxes within the Bax promoter/5'-UTR (Miyashita et al., 1995) . At present, there is no published evidence that c-Myc functions through these elements to induce Bax expression. As previously mentioned, TGFa appears to activate cellular survival pathways and induce the expression of the antiapoptotic protein Bcl-x L (Nass et al., 1996) . This work, combined with results from the characterization of MMTV-c-myc/WAP-bcl-2 bitransgenic mice, strongly suggests that mammary tumorigenesis is signi®cantly increased when deregulated c-myc expression, responsible both for driving cellular proliferation as well as increasing cellular sensitivity to apoptosis, is coupled with other genetic alterations that act as survival signals to block c-myc-mediated apoptotic pathways. In this latter study, bcl-2 expression accelerated mammary tumorigenesis and suppressed in vivo mammary tumor apoptosis (JaÈ ger et al., 1997).
p53 tumor suppressor gene, the mammae and breast cancer p53 is a 393-amino acid nuclear phosphoprotein transcription factor known to bind DNA upon stabilization induced by cell cycle checkpoint controls. p53 transactivation increases the expression of genes involved in such distinct processes as apoptosis, DNA repair, and cell cycle arrest (Evan et al., 1998; El-Deiry, 1998) . p53 has often been termed the`guardian of the genome' owing to the fact that it plays such a critical role as a tumor suppressor by orchestrating cell cycle arrest and DNA repair upon recognition of certain levels of DNA damage. Cell cycle inhibitory activities are believed to be controlled by p53-dependent transcriptional activation of genes, including p21/ WAF1/CIP1, 14-3-3s, and GADD45. In addition to its role in DNA damage recognition, the p53 tumor suppressor has also been linked to the recognition of oncogene activation (c-myc and adenovirus E1A), subsequently resulting in apoptosis induction via a pathway that includes ARF and MDM2 de Stanchina, et al., 1998; Sherr, 1998) . p53 is capable of promoting apoptosis upon recognition of severe, irreparable DNA damage, DNA damage in the context of other environmental conditions unfavorable for maintenance of genomic integrity, and abnormal cellular proliferation as driven by oncogene activation. Thus far, p53-dependent apoptosis has been demonstrated to result from the transcriptional activation of genes, including Bax, Fas/Apo1/CD95, and DR5 Trail receptor, and from transcriptional repression of the anti-apoptotic gene Bcl-2 (Canman et al., 1997; ElDeiry, 1998).
Little information exists concerning the expression pattern for wild-type p53 during development in either human or murine mammary glands. One study indicates that p53 mRNA is expressed during pregnancy and involution, but not during lactation (Strange et al., 1992) . Another study, however, suggests that the complete absence of p53 expression does not alter the histological or functional development of the mammae in mice, since p53 7/7 mice remain capable of lactation (Donehower et al., 1992) . As regards the role of p53 in mammary apoptosis, both p53-dependent and p53-independent apoptosis have been demonstrated in cultured MECs (Merlo et al., 1995) . In mice, one study has indicated that post-lactational mammary involution and apoptosis proceed normally without regard for p53 status ; whereas, another study has demonstrated that the ®rst phase of mammary involution is delayed in p53-null animals (Jerry et al., 1998) .
The p53 tumor suppressor is one of the most frequently altered genes in a wide variety of human cancers, including breast cancer . Breast cancer, along with sarcomas, brain tumors, leukemias and adrenal cortical tumors, is common among women with Li-Fraumeni Syndrome, a disorder linked to germline mutations in the p53 locus (Eeles et al., 1993) . Furthermore, p53 gene mutations have been identi®ed in approximately 17% of all human breast cancers (Dahiya and Deng, 1998) . To date, results in the mammary glands of murine p53-knockout animals have been somewhat discordant with expectations based on Li-Fraumeni Syndrome. Speci®cally, non-mammary gland tumors, such as lymphomas, rapidly arise in p53-knockout animals, suggesting that p53 is not of predominant importance in murine mammary tumor development (Donehower et al., 1992; Harvey et al., 1993; Purdie et al., 1994) . More recent investigations of human breast cancer-relevant p53 missense mutations expressed in transgenic models (Li et al., 1998) and wnt1 transgenic/p53-knockout murine models Jones et al., 1997) indicate that p53 alteration can be contributory to mammary tumorigenesis in some circumstances. It is possible that the lack of agreement concerning the role of p53 loss in murine models of cancer and human breast cancer results from interspecies dierences, from the modulation of tumorigenesis by murine strain dierences, from other transgenes carried in the background, and from the particular p53 genetic knockouts and mutations modeled in these mice. The latter dierence may be most signi®cant, since the mammary tumorigenic eects noted in the study of the p53-172R/H mutant transgenic mouse resulted from the rational modeling of a speci®c, human breast cancer-relevant p53 alteration (Li et al., 1998) .
MMTV-c-myc/p53
+/7 transgenic mice
In 1995, two transgenic models with a mammarytargeted oncogene (MMTV-wnt1 or MMTV-c-myc) and p53 de®ciency were established to determine whether or not de®ciencies in the tumor suppressor p53 could cooperate with deregulated expression of Wnt1 or c-Myc to alter tumorigenesis in mammary tissues Elson et al., 1995) . A cooperative eect was indeed observed between Wnt1 and p53 de®ciency, as mammary tumors in the MMTV-wnt1/p53 7/7 mice arose sooner and had a signi®cantly higher degree of chromosomal instability than those of MMTV-wnt1/p53 +/7 and MMTV-wnt1/ p53 +/+ animals . In the MMTV-c-myc model, animals with p53 disruption rapidly developed lethal lymphomas, indicating that c-myc and mutant p53 had a cooperative eect in terms of increasing the incidence and accelerating the onset of T-cell lymphomas. However, p53 disruption failed to in¯uence the mammary adenocarcinoma phenotype of the MMTV-c-myc animals. In those MMTV-c-myc/p53 +/7 female mice that survived their lymphomas long enough to acquire mammary tumors, there was no identi®able alteration in tumor latency, histology, or dependence upon pregnancy as compared with MMTV-c-myc/p53 +/+ controls (Elson et al., 1995) . The absence of cooperation between p53 and c-Myc in terms of mammary carcinogenesis in this model may re¯ect intrinsic dierences between murine and human mammary tumorigenesis, the cooperation between c-myc and p53 in inducing extremely aggressive lymphomas that limited the mammary observation window, or the speci®c manner in which the p53 alleles were targeted. It has been demonstrated that most p53 alterations in human breast cancers are missense mutations that may in¯uence the activity of the p53 gene product, rather than deletions of entire p53 exons (as was done in both of the previously mentioned models) that are capable of completely eliminating all p53 functionality (Elson et al., 1995; Lozano et al., 1998) . This particular fact suggests that a cross between the p53-172R/H mutant transgenic mouse and WAP-cmyc or MMTV-c-myc transgenic mouse might be more relevant to the study of breast cancer. Unfortunately, there is no evidence to date concerning the frequency or relevance of combined c-myc ampli®cation/overexpression and p53 mutation in human breast tumors.
Recently, our group generated transgenic mice in which the mammary-targeted c-myc oncogene was expressed in the presence of a targeted disruption of the p53 tumor suppressor gene (McCormack et al., 1998) . Although our results indicated that disruption of p53 may contribute to alveolar hyperplastic changes in the virgin female transgenic mouse, they failed to show any cooperation between c-myc and p53 disruption in mammary tumorigenesis, since no alterations in latency, histology, or apoptosis were observed between c-myc-induced mammary tumors in animals with or without disrupted p53 (McCormack et al., 1998) . To determine whether or not disruption of p53 could in¯uence c-myc-induced chromosomal instability in mammary tumors from these transgenic mice, tumorderived cell lines were subjected to spectral karyotyping (SKY) analysis (Liyanage et al., 1996) . This analysis demonstrated that p53 disruption did not signi®cantly in¯uence ploidy or other c-myc-induced chromosomal alterations. Analysis of these p53 +/+ and p53 +/7 tumor cells lines using both SKY and comparative genomic hybridization (CGH) also supported the concept that c-myc-induced chromosomal instability is unaected by p53 status (McCormack et al., 1998; Weaver et al., 1999) . Unfortunately, the eects of complete p53 disruption in the presence of c-myc transgene expression were untestable due to rapidly arising lymphomas that forced us to limit the duration of mammary observations.
Summary and future directions
Recent progress in the study of c-Myc has convincingly demonstrated that it possesses a dual role in promoting cellular proliferation and apoptosis. Work from our group and others has con®rmed this dual role of c-Myc in murine mammae and has further shown that co-expression of TGFa can synergistically accelerate mammary tumorigenesis as well as abrogate tumor reliance on estrogenic signalling. These results appear similar to those obtained for c-myc/v-Ha-ras bitransgenic mice and further suggest that signalling through the EGFR (as well as activation of Ras) may induce downstream survival-signalling pathways that impinge upon c-Myc-driven apoptosis. Currently, work is being conducted in our laboratory with mammary tumor cell lines derived from the bitransgenic mice to resolve the nature and contribution of these survival pathways. The contribution of p53 mutation to breast tumorigenesis in humans is well established. Nevertheless, several studies suggest that p53 loss does not functionally or physically alter the murine mammae. Work from our group and another group has indicated a lack of obvious cooperation between hemizygous p53 knockout and c-myc transgene expression in bitransgenic mice. Unfortunately, the nature of these two models precluded the examination of the eect of homozygous p53 loss on mammary tumorigenesis due to the pervasive and aggressive lymphomas that arose in these animals. As was suggested by work with the p53-172R/H mutant mouse, it would be worth examining the contribution of breast cancer-speci®c p53 point mutants to c-mycinduced mammary tumorigenesis.
Of signi®cant interest to those who study breast cancer and c-Myc is the nature of apoptosis signalling by c-Myc and its contribution to breast tumorigenesis. Greater resolution of this apoptotic pathway could suggest additional targets for breast cancer therapies. Work described herein provides the basis for the development of other combinatorial, mammary-speci®c transgenic models that will further dissect the relationship between c-Myc and apoptosis.
